WO2003080581A1 - Phenanthridinones as parp inhibitors - Google Patents
Phenanthridinones as parp inhibitors Download PDFInfo
- Publication number
- WO2003080581A1 WO2003080581A1 PCT/JP2003/003579 JP0303579W WO03080581A1 WO 2003080581 A1 WO2003080581 A1 WO 2003080581A1 JP 0303579 W JP0303579 W JP 0303579W WO 03080581 A1 WO03080581 A1 WO 03080581A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- nmr
- dmso
- mixture
- mass
- Prior art date
Links
- 0 CC(*)(CCC1C(CCCC2)C2N2)CC1C2=O Chemical compound CC(*)(CCC1C(CCCC2)C2N2)CC1C2=O 0.000 description 2
- WGEOVEXGUHZJAV-UHFFFAOYSA-N CCC(NC(C=C=CC1)=CC1N)=O Chemical compound CCC(NC(C=C=CC1)=CC1N)=O WGEOVEXGUHZJAV-UHFFFAOYSA-N 0.000 description 1
- OLTMNRUSRKEKNZ-UHFFFAOYSA-N CCCC(C(C)C(CCCC1)C1N1)C1=O Chemical compound CCCC(C(C)C(CCCC1)C1N1)C1=O OLTMNRUSRKEKNZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
- C07D221/12—Phenanthridines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- This invention relates to novel tricyclic compounds having a pharmacological activity, a process for their production and a pharmaceutical composition containing the same.
- PARP Poly(adenosine 5'-diphospho-ribose)polymerase
- NAD nicotinamide adenine dinucleotide
- PARP inhibitors are expected to be useful in treatment and prevention of various diseases ascribed by NMDA- and NO-induced toxicity.
- benzi idazole derivatives having inhibitory activity of PARP have been known, for example, in WO00/29384, WO00/32579, WO00/68206 and WO01/21615.
- a further object of this invention is to provide a pharmaceutical composition containing an effective amount of the tricyclic compound, its prodrug or a pharmaceutically acceptable salt thereof, which has a PARP inhibiting activity, as an active ingredient in admixture of a pharmaceutically acceptable carrier.
- Still further object of this invention is to provide a use of the tricyclic compound, its prodrug or a pharmaceutical acceptable salt thereof for preparing a medicament for treating or preventing diseases ascribed by excess activation of PARP.
- Still further object of the invention is to provide a method of treating or preventing diseases ascribed by excess activation of PARP by administering the tricyclic compound, its prodrug or a pharmaceutical acceptable salt thereof in an effective amount to inhibit PARP activity.
- ring A is a carbocyclic group
- R 1 is hydrogen or a halogen atom or a lower alkyl group
- R 2 is a di (lower) alkylamino group or N-containing heterocyclic group, among which the N-containing heterocyclic group may be substituted with one or more substituent(s)
- Y is an oxygen or sulfur atom
- n is an integer from 0 to 2
- m is an integer from 0 to 4.
- lower means a group having 1 to 6 carbon atom(s), unless otherwise provided.
- one or more means 1 to 6, preferably 1 to 3, and more preferably 1 or 2.
- Suitable examples of the lower alkyl group and the lower alkyl moiety in the ⁇ -U(lower)alkylamino group are straight or branched ones having 1 to 6 carbon atoms such as methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-ethylbutyl, isobutyl, tert-butyl, pentyl, n-hexyl, etc.
- halogen atom Suitable examples of the halogen atom are fluorine, chlorine, bromine or iodine.
- Suitable examples of the carbocyclic group are cyclo (lower) alkane ring (e.g., cyclobutane, cyclopentane, cyclohexane or cycloheptane), cyclo (lower) alkene ring (e.g., cyclopentene or cyclohexene) and aromatic hydrocarbon ring (e.g., benzene or naphthalene).
- cyclo (lower) alkane ring e.g., cyclobutane, cyclopentane, cyclohexane or cycloheptane
- cyclo (lower) alkene ring e.g., cyclopentene or cyclohexene
- aromatic hydrocarbon ring e.g., benzene or naphthalene
- N-containing heterocyclic group is monocyclic or condensed heterocyclic groups containing 1 to 4 nitrogen atom(s) and optionally 1 to 2 oxygen or sulfur atom.
- N-containing heterocyclic group are: (1) unsaturated 3 to 7-membered, preferably 5- or 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms, for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, tetrahydropyridyl, pyrimidinyl, tetrahydropyrimidinyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-l,2,4-triazolyl, lH-l,2,3-triazolyl or 2H-l,2,3-triazolyl) or tetrazolyl (e.g., lH-tetrazolyl or 2H-tetrazolyl),
- unsaturated 3 to 7-membered, preferably 5- or 6-membered heteromonocyclic group containing 1 to 3 nitrogen atoms and 1 to 2 oxygen atoms for example, oxazolyl, isoxazolyl or oxadiazolyl (e.g., 1,2,4-oxadiazolyl, 1,2,4-oxadiazolinyl, 1,3,4-oxadiazolyl or 1 ,2 , 5-oxadiazolyl) ;
- unsaturated 3 to 7-membered, preferably 5- or 6-membered heteromonocyclic group containing 1 to 3 nitrogen atoms and 1 to 2 sulfur atoms for example, thiazolyl or thiadiazolyl (e.g., 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl or 1,2,5-thiadiazolyl), (6) saturated 3 to 7-membered preferably 5- or 6-membered heteromonocyclic group containing 1 to 3 nitrogen atoms and 1 to 2 sulfur atoms, for example, thiomorpholinyl or thiazolidinyl,
- unsaturated condensed heterocyclic group containing 1 to 3 nitrogen atoms for example, benzopyrrolyl, benzi idazolyl, benzopyrazolyl, benzotriazolyl, quinolyl, isoquinolyl, indolyl, indolinyl, isoindolidinyl, 1,2,3,4-tetrahydroquinolyl or pyrido[3,4-b]indolyl,
- unsaturated condensed heterocyclic group containing 1 to 3 nitrogen atoms and 1 to 2 oxygen atoms for example, benzoxazolyl, benzoxadiazolyl or phenoxazinyl; or
- (9) unsaturated condensed heterocyclic group containing 1 to 3 nitrogen atoms and 1 to 2 sulfur atoms for example, benzothiazolyl, benzisothiazolyl or phenothiazinyl.
- heterocyclic group is an unsaturated 5- or 6-membered heteromonocyclic group as mentioned in the above (1) or a saturated 5- or 6-membered heteromonocyclic group as mentioned in the above (2) and (4), among which the most preferable one is pyridyl, tetrahydropyridyl, piperidyl, piperazinyl or morpholinyl.
- the N-containing heterocyclic group and l,3,4,9-tetrahydro-2H- ⁇ -carbolin-2-yl group may be optionally substituted with one or more substituent(s) such as hydroxy; amino; carboxy; cyano; nitro; carbamoyl; oxo; halogen (e.g., fluorine, bromine or chlorine); lower alkyl (e.g., methyl, ethyl, isopropyl or tert-butyl); lower alkoxy (e.g., methoxy, ethoxy, butoxy or n-propoxy); halo (lower) alkyl (e.g., chloromethyl or trifluoromethyl); optionally substituted aryl [e.g., naphthyl or phenyl which may be further substituted with halogen (e.g., fluorine, bromine or chlorine), lower alkoxy (e.g., methoxy, ethoxy, butoxy or
- Suitable salts of the compound (I) are pharmaceutically acceptable, conventional and non-toxic salts, for example an organic acid addition salt (e.g. formate, acetate, trifluoroacetate, maleate, tartarate, oxalate, methanesulfonate, benzenesulfonate or toluenesulfonate), an inorganic acid addition salt (e.g. hydrochloride, hydrobromide, sulfate or phosphate), a salt with an amino acid (e.g. aspartate or glutamate), or the like.
- organic acid addition salt e.g. formate, acetate, trifluoroacetate, maleate, tartarate, oxalate, methanesulfonate, benzenesulfonate or toluenesulfonate
- an inorganic acid addition salt e.g. hydrochloride, hydrobromide, sulfate or phosphate
- the compounds (I) may contain one or more asymmetric centers and thus they can exist as enantiomers or diastereoisomers.
- the compounds (I) may also exist in tautomeric forms and the invention includes both mixtures and separate individual tautomers.
- the compound (I) and its salt can be in a form of a solvate, which is also included within the scope of the present invention.
- the solvate preferably include a hydrate and an ethanolate.
- radiolabelled derivatives of compounds (I) which are suitable for biological studies.
- the “prodrug” may be a derivative of the compound (I) having a chemically or metabolically degradable group, which becomes pharmaceutically active substance after biotransformation.
- Preferred compounds (I) are the ones ring A is a cyclo (lower) alkane ring or aromatic hydrocarbon ring,
- R 1 is hydrogen or a halogen atom
- n is an integer of 0 or 1
- R 2 , Y and m have the same meaning as defined in the above.
- More preferred compounds (I) are the ones wherein R 2 is tetrazolyl, pyridyl, piperidyl, piperazinyl, morpholinyl, isoindolidinyl or pyrido[3,4-b]indolyl, each of which may be substituted with one or more substituent(s) .
- R 2 , Y, n and m have the same meaning as defined in the above, and the ones wherein the ring A is a benzene ring, R 1 is hydrogen or a halogen atom,
- R 2 and Y have the same meaning as defined in the above, n is 0, and m is an integer 3 or 4.
- Especially preferred compounds (I) are those wherein the ring A is a cyclohexane ring, R 1 is hydrogen atom, R 2 has the same meaning as defined in the above, Y is an oxygen atom, n is an integer of 0 or 1, and m is an integer from 0 to 3.
- the compound (I) or a salt thereof can be prepared by the following processes.
- R 1 , R 2 , Y, n, m and the ring A are each as defined above, X is a leaving group, R 3 and R 4 are each lower alkyl group, Y x s are independently a hidroxy group or oxygen atom and/ or together represent an oxo group or ethylene ketal or propylene ketal group,
- 2 ⁇ is a N-containing heterocyclic group or l,3,4,9-tetrahydro-2H- j3 -carbolin-2-yl group, both of which may be optionally substituted with one or more substituent(s),
- N — N ⁇ z 2 J i is a N-containing heterocyclic group which may be optionally substituted with one or more substituent(s),
- Suitable leaving group may be halogen (e.g., fluoro, chloro, bromo or iodo), arylsulfonyloxy (e.g., benzenesulfonyloxy or tosyloxy), alkylsulfonyloxy (e.g., mesyloxy or ethanesulfonyloxy) or the like, among which the preferable one is halogen.
- halogen e.g., fluoro, chloro, bromo or iodo
- arylsulfonyloxy e.g., benzenesulfonyloxy or tosyloxy
- alkylsulfonyloxy e.g., mesyloxy or ethanesulfonyloxy
- the object compound (1-1) or its salt can be prepared by reacting a compound (II) or its salt with a compound (III- 1 ) or its salt. This reaction is usually carried out in the presence of an inorganic or an organic base.
- Suitable inorganic base may be an alkali metal [e.g., sodium or potassium], an alkali metal hydroxide [e.g., sodium hydroxide or potassium hydroxide], alkali metal hydrogen carbonate [e.g., sodium hydrogen carbonate or potassium hydrogen carbonate], alkali metal carbonate [e.g., sodium carbonate or potassium carbonate], alkaline earth metal carbonate [e.g., calcium carbonate or magnesium carbonate], alkali metal hydride [e.g., sodium hydride or potassium hydride], or the like.
- alkali metal e.g., sodium or potassium
- an alkali metal hydroxide e.g., sodium hydroxide or potassium hydroxide
- alkali metal hydrogen carbonate e.g., sodium
- Suitable organic base may be tri (lower) alkylamine [e.g., triethylamine or N,N-diisopropylethylamine], alkyl magnesium bromide [e.g., methyl magnesium bromide or ethyl magnesium bromide], alkyl lithium [e.g., methyl lithium or butyl lithium], lithium diisopropylamide, lithium hexamethyldisilazido, or the like.
- tri (lower) alkylamine e.g., triethylamine or N,N-diisopropylethylamine
- alkyl magnesium bromide e.g., methyl magnesium bromide or ethyl magnesium bromide
- alkyl lithium e.g., methyl lithium or butyl lithium
- lithium diisopropylamide lithium hexamethyldisilazido, or the like.
- the reaction is usually carried out in a conventional solvent such as an alcohol [e.g., methanol, ethanol, propanol or isopropanol], aromatic hydrocarbon [e.g., benzene, toluene or xylene], ethyl acetate, acetonitrile, dioxane, chloroform, methylene chloride, N,N-dimethylformamide or any other organic solvent which does not adversely influence the reaction.
- a conventional solvent such as an alcohol [e.g., methanol, ethanol, propanol or isopropanol], aromatic hydrocarbon [e.g., benzene, toluene or xylene], ethyl acetate, acetonitrile, dioxane, chloroform, methylene chloride, N,N-dimethylformamide or any other organic solvent which does not adversely influence the reaction.
- aromatic hydrocarbon e.g., benzene, tolu
- the reaction temperature is not critical , and the reaction is usually carried out under cooling to heating.
- the object compound (1-2) or its salt can be prepared by reacting a compound (IV) or its salt with a compound (III-2) or its salt.
- Suitable inorganic base may be an alkali metal alkoxide [e.g., sodium methoxide, potassium ethoxide or sodium tert-butoxide], or the like.
- Suitable binaphthyl compound may be 2 ,2'-bis(diphenylphophino)- 1 , 1 '-binaphthyl.
- Suitable palladium compound may be tris(dibenzylideneacetone)dipalladium (0).
- the reaction is usually carried out in a conventional solvent such as aromatic hydrocarbon [e.g., benzene, toluene or xylene], ethyl acetate, acetonitrile, dioxane, N,N-dimethylformamide or any other organic solvent which does not adversely influence the reaction.
- aromatic hydrocarbon e.g., benzene, toluene or xylene
- ethyl acetate ethyl acetate
- acetonitrile e.g., dioxane, N,N-dimethylformamide or any other organic solvent which does not adversely influence the reaction.
- the reaction is usually carried out at the temperature higher than 100 °C, preferably around 140 °C in a sealed tube.
- the object compound (1-3) or its salt can be prepared by reacting a compound (IV) or its salt with a compound (III-3) or its salt in a similar manner to the above Process 2.
- the object compound (1-4) or its salt can be prepared by reacting a compound (V) or its salt with a compound (VI) or its salt. This reaction is usually carried out in the presence of an inorganic or an organic base. Suitable inorganic base and organic base are the same as those exemplified in the above Process 1.
- the reaction is usually carried out in a conventional solvent such as an alcohol [e.g., methanol, ethanol, propanol or isopropanol], aromatic hydrocarbon [e.g., benzene, toluene or xylene], ethyl acetate, acetonitrile, dioxane, chloroform, methylene chloride, N,N-dimethylformamide, dimethylsulfoxide or any other organic solvent which does not adversely influence the reaction.
- a conventional solvent such as an alcohol [e.g., methanol, ethanol, propanol or isopropanol], aromatic hydrocarbon [e.g., benzene, toluene or xylene], ethyl acetate, acetonitrile, dioxane, chloroform, methylene chloride, N,N-dimethylformamide, dimethylsulfoxide or any other organic solvent which does not adversely influence the reaction.
- aromatic hydrocarbon
- the reaction is usually carried out at the temperature higher than 100 °C, preferably around 130 °C.
- the object compound (1-1) or its salt can be prepared by reacting a compound (VII) or its salt with a compound (III-l) or its salt in a similar manner to the above Process 1 and then treating with hydrochloric acid.
- the object compound (1-5) or its salt can be prepared by reacting a compound (VIII) or its salt with a trialkyl orthoformate and an azide compound.
- reaction can be carried out in a conventional organic acid such as acetic acid or propionic acid under heating.
- the object compound (1-6) can be prepared by reacting a compound (IX) with a 3-fluorophthalic anhydride and then treating the reaction product with perchloric acid, and then with sulfuric acid.
- the reaction can be carried out in a halogenated solvent such as methylene chloride, chloroform, carbon tetrachlori.de, 1,2-dicholoroethane, at a temperature cooling to heating.
- compounds (1-1), (1-2), (1-3), (1-4), (1-5) and (1-6) can be purified by a conventional purification method such as recrystallization, column chromatography, thin-layer chromatography, high-performance liquid chromatography or the like.
- the compound (I) can be identified by a conventional method such as NMR spectrography, mass spectrography, infrared spectrography, elemental analysis, or measurement of melting point.
- the recombinant human PARP (5.3mg protein/ml) was incubated with a test compound in a lOO ⁇ l reaction buffer containing an indicated concentration of 1 mCi/ml 32 P-NAD, 50mM Tris-HCl, 25mM MgCl 2 , ImM DTT (dithiothreitol), 0.05mM NAD (nicotinamide adenine dinucleotide) and 1 mg/ml activated DNA, pH8.0. Incubation was carried out for 15 minutes at a room temperature, and the reaction was stopped by addition of 200 ⁇ l of ice-cold 20% tricholoroacetic acid followed by rapid filtration through GF/B filters. The filtrate was treated with scintillation fluid and acid-insoluble counts were measured for quantification of unit activity.
- the compounds (I) have a potent PARP inhibitory activity as shown in the above.
- PARP inhibitors of this invention were effective in preventing reduction of striatal DA(dopamine) and its metabolite induced by MPTP (N-methyl-l,2,3,6-tetrahydropyridine) treatment in mice. Therefore, it is suggested that these compounds may have protective benefit in the treatment of neurodegenerative disease such as Parkinson's disease.
- Such diseases include, for example, tissue damage resulting from cell damage or death due to necrosis or apoptosis; neural tissue damage resulting from ischemia and reperfusion injury, neurological disorders and neurodegenerative diseases; neurodegenerative diseases; head trauma; stroke; Alzheimer's disease; Perkinson's disease; epilepsy; amyotrophic lateral scleosis (ALS); Huntington's disease; schizophrenia; chronic pain; ischemia and neuronal loss following hypoxia; hypoglycemia; ischemia; trauma; and nervous insult.
- PARP inhibitor is useful in reducing infarct size (Thiemermann et al, Proc. Natl. Acad. Sci. USA, 94: 679-83 (1997)). Therefore, the compound (I) of this invention and a pharmaceutically acceptable salt thereof possessing PARP inhibiting activity are useful in treatment and prevention of previously ischemic heart or skeleton muscle tissue.
- the compound (I) of this invention and a pharmaceutically acceptable salt thereof possessing PARP inhibiting activity are effective in treating and preventing radiosensitizing hypoxic tumor cells; tumor cells from recovering from potentially lethal damage of DNA after radiation therapy.
- the compound (I) of this invention and a pharmaceutically acceptable salt thereof possessing PARP inhibiting activity are useful in extending the life-span and proliferative capacity of cells and altering gene expression of senescent cells. They are useful for treating and preventing skin aging; Alzheimer's diseases; atheroscleosis; osteoarthritis; osteoporosis; muscular dystrophy; degenerative diseases of skeletal muscle involving replicative senescence; age-related macular degeneration; immune senescence; AIDS; and other immune senescence diseases.
- the compound (I) of this invention and a pharmaceutically acceptable salt thereof possessing PARP inhibiting activity are effective in treating and preventing inflammatory bowel disorders (e.g., colitis); arthritis; diabetes; endotoxic shock; septic shock; and tumor. Also, the compounds (I) are useful in reducing proliferation of tumor cells and making synergistic effect when tumor cells are co-treated with an alkylating drug.
- the compound (I) of this invention and a pharmaceutically acceptable salt thereof possessing PARP inhibiting activity are effective in treating and preventing pituitary apoplexy; conjunctivitis; retinoblastoma; retinopathy; acute retinal necrosis syndrome; Sjogren's syndrome.
- the present invention provides a method for treating or preventing diseases ascribed by NMDA- and NO-induced toxicity by administering a compound (I), its prodrug, or a pharmaceutically acceptable salt thereof in an effective amount to inhibit PARP activity, to a human being or an animal who needs to be treated or prevented.
- the compound (I), its prodrug or their salt can be administered alone or in the form of a mixture, preferably, with a pharmaceutical vehicle or carrier.
- a pharmaceutical composition comprising a compound (I), its prodrug or a pharmaceutically acceptable salt thereof as an active ingredient in admixture with a pharmaceutically acceptable carrier such as an organic or inorganic carrier or excipient suitable for external (topical), enteral, intravenous, intramuscular, parenteral or intramucous applications in a pharmaceutical preparation, for example, in solid, semisolid or liquid form.
- the compound (I), its prodrug or a pharmaceutical acceptable salt thereof can be formulated, for example, with the conventional non-toxic, pharmaceutically acceptable carriers for ointment, cream, plaster, tablets, pellets, capsules, suppositories, solution (saline, for example), emulsion, suspension (olive oil, for example), aerosols, pills, powders, syrup, injection, troches, cataplasms, aromatic water, lotion, buccal tablets, sublingual tablets, nasal drop or any other form suitable for use.
- the carriers which can be used are water, wax, glucose, lactose, gum acacia, gelatin, mannitol, starch paster, magnesium trisilicate, talc, corn starch, keratin, paraffin, colloidal silica, potato starch, urea and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form, and in addition to the above auxiliary, stabilizing, thickening or coloring agent and perfume may be used.
- the compound (I), its prodrug or a pharmaceutical acceptable salt thereof can be formulated into, for example, preparations for oral application, preparations for injection, preparations for external application, preparations for inhalation, preparations for application to mucous membranes.
- the present invention provides a pharmaceutical composition containing a compound (I), its prodrug or a pharmaceutical acceptable salt thereof in admixture of a pharmaceutically acceptable salt for treating or preventing diseases ascribed by NMDA- and NO-induced toxicity, specifically for extending the lifespan or proliferative capacity of cells or altering gene expression of senescent cells, more specifically for treating or preventing diseases ascribed by excess activation of
- PARP such as tissue damage resulting from cell damage or death due to necrosis or apoptosis; neural tissue damage resulting from ischemia and reperfusion injury, neurological disorders and neurodegenerative diseases; neurodegenerative diseases; head trauma; stroke; Alzheimer's disease; Perkinson's disease; epilepsy; Amyotrophic Lateral Scleosis (ALS); Huntington's disease; schizopherenia; chronic pain; ischemia and neuronal loss following hypoxia; hypoglycemia; ischemia; trauma; nervous insult; previously ischemic heart or skeleton muscle tissue; radiosensitizing hypoxic tumor cells; tumor cells from recovering from potentially lethal damage of DNA after radiation therapy; skin aging; atheroscleosis; osteoarthritis; osteoporosis; muscular dystrophy; degenerative diseases of skeletal muscle involving replicative senescence; age-related macular degeneration; immune senescence; AIDS; and other immune senescencediseases; inflammatory bowel disorders (e.g.
- Mammals which may be treated by the present invention include livestock mammals such as cows, horses, etc., domestic animals such as dogs, cats, rats, etc. and human beings, preferably human beings. While the dosage of therapeutically effective amount of the compound (I) varies depending on the age and condition of each individual patient, an average single dose of about 0.01 mg, 0.1 mg, 1 mg, 10 mg, 50 mg, 100 mg, 250 mg, 500 mg, and 1000 mg of the compound (I) may be effective for treating the above-mentioned diseases. In general, amounts between 0.01 mg/body and about 1,000 mg/body may be administered per day.
- phenylboronic acid (437mg), 2M aqueous solution of sodium dicarbonate (4.5ml) and tetrakis(triphenylphosphine)palladium (0) (173mg) were added to a solution of ethyl 2-bromo-4-(3-bromopropyl)phenylcarbamate (l. lg) in dimethoxyethane (13.5ml) at room temperature. The mixture was refluxed for 5 hours. After cooling to room temperature, the mixture was poured into a mixture of water and EtOAc. The separated organic layer was washed with brine and dried over magnesium sulfate.
- Trifluoroacetic acid 13ml was added to a solution of tert-butyl 4-(3-bromopropyl)phenylcarbamate (5.25g) in DCM at room temperature. The mixture was stirred for 4 hours. After evaporation of the solvent, diethyl ether was added to the residue to wash the crude product. After the ethereal layer was removed by decantation, the resulting crude oil was diluted with EtOAc. After adding 4N hydrogen chloride in EtOAc (10ml) to the solution, the resulting precipitate was collected by filtration, washed with EtOAc and dried in vacuo to give 3-(3-bromopropyl)aniline hydrochloride (2.32g).
- Oxalyl chloride (1.14g) was added dropwise to a solution of l,4-dioxaspiro[4,5]decane-6-carboxylic acid (559mg) and DMF (ldrop) in DCM (5ml), and the mixture was stirred for 2 hours at room temperature. After removing the solvent under reduced pressure, the residue was dissolved in DCM (5ml). The solution was added dropwise to a solution of 3-(3-bromopropyl)aniline hydrochloride (752mg) and triethylamine (1.67ml) in DCM (10ml). The solution was stirred for 2 hours at room temperature and poured into a mixture of water and DCM.
- Oxaryl chloride (3.82g) and 1 drop of DMF were added successively to a solution of l,4-dioxaspiro[4,5]decane-6-carboxylic acid (1.87g) in DCM (15ml) at room temperature. The solution was stirred for 2 hours at room temperature and the solvent was evaporated. The residue was diluted with DCM (5ml) and added dropwise to a mixture of 3-nitroaniline (1.39g) and triethylamine (3.05g) in DCM (8.5ml) under ice cooling. After 10 minutes the ice bath was removed and the mixture was stirred at room temperature for 1.5 hours and poured into a mixture of water and EtOAc.
- N-(3-aminophenyl)-l,4-dioxaspiro[4,5]decane-6-carboxarnide (1.24 g).
- Example 24 3-[3-(4-Morpholinyl) ⁇ ropyl]-7,8,9,10-tetrahydro-6(5H)- phenanthridinone hydrochloride IR (KBr) cm- i : 3276, 1625, 1567.
- Example 45 4-Fluoro-2-(6-oxo-5,6,7,8,9, lO-hexahydro-3-phenanthridinyl)- lH-isoindol-l,3(2H)-dione was obtained in a similar manner to
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Structural Engineering (AREA)
- Materials Engineering (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/508,004 US20050171101A1 (en) | 2002-03-26 | 2003-03-25 | Phenanthridinones as parp inhibitors |
EP03712891A EP1487800A1 (en) | 2002-03-26 | 2003-03-25 | Phenanthridinones as parp inhibitors |
JP2003578336A JP2005521698A (en) | 2002-03-26 | 2003-03-25 | New tricyclic compounds |
AU2003217491A AU2003217491A1 (en) | 2002-03-26 | 2003-03-25 | Phenanthridinones as parp inhibitors |
CA002480384A CA2480384A1 (en) | 2002-03-26 | 2003-03-25 | Phenanthridinones as parp inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPS1374A AUPS137402A0 (en) | 2002-03-26 | 2002-03-26 | Novel tricyclic compounds |
AUPS1374 | 2002-03-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003080581A1 true WO2003080581A1 (en) | 2003-10-02 |
Family
ID=3834964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/003579 WO2003080581A1 (en) | 2002-03-26 | 2003-03-25 | Phenanthridinones as parp inhibitors |
Country Status (6)
Country | Link |
---|---|
US (1) | US20050171101A1 (en) |
EP (1) | EP1487800A1 (en) |
JP (1) | JP2005521698A (en) |
AU (1) | AUPS137402A0 (en) |
CA (1) | CA2480384A1 (en) |
WO (1) | WO2003080581A1 (en) |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US7196085B2 (en) | 2002-04-30 | 2007-03-27 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
WO2008090379A1 (en) * | 2007-01-24 | 2008-07-31 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Pyrazoloquinazolinones as inhibitors of poly(adp-ribose)polymerase (parp) |
US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US7470688B2 (en) | 2005-10-19 | 2008-12-30 | Maybridge Limited | Phthalazinone derivatives |
WO2009041565A1 (en) * | 2007-09-26 | 2009-04-02 | Santen Pharmaceutical Co., Ltd. | Quinazolinone derivative, and prophylactic or therapeutic agent for corneal/conjunctival disorder comprising quinazolinone derivative as active ingredient |
WO2009041566A1 (en) * | 2007-09-26 | 2009-04-02 | Santen Pharmaceutical Co., Ltd. | Preventive or remedy for posterior eye diseases containing quinazolinone derivative or quinoxaline derivative as the active ingredient |
WO2009061131A2 (en) * | 2007-11-06 | 2009-05-14 | Je Il Pharmaceutical Co., Ltd. | Novel tricyclic derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same |
EP2305221A1 (en) | 2003-12-01 | 2011-04-06 | Kudos Pharmaceuticals Limited | Dna damage repair inhibitors for treatment of cancer |
WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
US20110230491A1 (en) * | 2003-12-05 | 2011-09-22 | Dominique Jean-Pierre Mabire | 6-substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors |
US8168644B2 (en) | 2008-03-27 | 2012-05-01 | Janssen Pharmaceutica Nv | Quinazolinone derivatives as tubulin polymerization inhibitors |
US8299256B2 (en) | 2007-03-08 | 2012-10-30 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP and TANK inhibitors |
US8404713B2 (en) | 2007-10-26 | 2013-03-26 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP inhibitors |
US8475842B2 (en) | 2008-10-07 | 2013-07-02 | Astrazeneca Ab | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
US8524714B2 (en) | 2003-11-20 | 2013-09-03 | Janssen Pharmaceutica, Nv | 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors |
US8623872B2 (en) | 2004-06-30 | 2014-01-07 | Janssen Pharmaceutica, Nv | Quinazolinone derivatives as PARP inhibitors |
US8889866B2 (en) | 2008-03-27 | 2014-11-18 | Janssen Pharmaceutica, Nv | Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors |
US8912187B2 (en) | 2003-03-12 | 2014-12-16 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US8946221B2 (en) | 2004-06-30 | 2015-02-03 | Janssen Pharmaceutica, Nv | Phthalazine derivatives as PARP inhibitors |
CN104507941A (en) * | 2012-07-31 | 2015-04-08 | 百时美施贵宝公司 | Aryl lactam kinase inhibitors |
US9163003B2 (en) | 2011-07-13 | 2015-10-20 | Novartis Ag | 4-piperidinyl compounds for use as tankyrase inhibitors |
US9181266B2 (en) | 2011-07-13 | 2015-11-10 | Novartis Ag | 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors |
US9227982B2 (en) | 2011-07-13 | 2016-01-05 | Novartis Ag | 4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrminidinyl compounds for use as tankyrase inhibitors |
WO2018197461A1 (en) | 2017-04-28 | 2018-11-01 | Akribes Biomedical Gmbh | A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing |
EP3312177A4 (en) * | 2015-06-09 | 2018-12-05 | Jeil Pharmaceutical Co., Ltd. | Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same |
WO2019175132A1 (en) | 2018-03-13 | 2019-09-19 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
WO2021048235A1 (en) | 2019-09-10 | 2021-03-18 | The Francis Crick Institute Limited | Treatment of hr deficient cancer |
WO2022228387A1 (en) * | 2021-04-26 | 2022-11-03 | Fochon Biosciences, Ltd. | Compounds as parp inhibitors |
US11591331B2 (en) | 2021-04-19 | 2023-02-28 | Xinthera, Inc. | PARP1 inhibitors and uses thereof |
US11795173B1 (en) | 2022-04-28 | 2023-10-24 | Xinthera, Inc. | Substituted pyridines as PARP1 inhibitors |
US11802128B2 (en) | 2021-10-01 | 2023-10-31 | Xinthera, Inc. | Azetidine and pyrrolidine PARP1 inhibitors and uses thereof |
US11939329B2 (en) | 2022-01-21 | 2024-03-26 | Xinthera, Inc. | PARP1 inhibitors and uses thereof |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4866610B2 (en) * | 2003-08-18 | 2012-02-01 | 富士フイルムファインケミカルズ株式会社 | Pyridyltetrahydropyridines and pyridylpiperidines |
NZ587586A (en) * | 2005-07-18 | 2012-04-27 | Bipar Sciences Inc | Treatment of cancer |
BRPI0707902A2 (en) * | 2006-02-15 | 2011-05-17 | Abbott Lab | Pyrazoloquinolones are potent inhibitors for |
WO2008028168A2 (en) * | 2006-09-01 | 2008-03-06 | Cylene Pharmaceuticals, Inc. | Serine-threonine protein kinase and parp modulators |
CN102379884A (en) | 2006-09-05 | 2012-03-21 | 彼帕科学公司 | Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof |
AU2007292387A1 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
EP2114948B1 (en) * | 2006-12-28 | 2014-06-25 | AbbVie Inc. | Inhibitors of poly(adp-ribose)polymerase |
SG185952A1 (en) | 2007-11-12 | 2012-12-28 | Bipar Sciences Inc | Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents |
CA2713156A1 (en) * | 2008-02-04 | 2009-08-13 | Bipar Sciences, Inc. | Methods of diagnosing and treating parp-mediated diseases |
SA109300394B1 (en) * | 2008-06-19 | 2013-01-22 | ويث | Thiazolyl- and oxazolyl-isoquinolinones and methods for using them |
JP5632368B2 (en) * | 2008-06-19 | 2014-11-26 | ワイス・エルエルシー | Thienyl- and furanyl-isoquinolinones and methods for their use |
MX2011004957A (en) * | 2008-11-11 | 2011-08-12 | Je Il Pharmaceutical Co Ltd | Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same. |
WO2010111626A2 (en) * | 2009-03-27 | 2010-09-30 | Takeda Pharmaceutical Company Limited | Poly (adp-ribose) polymerase (parp) inhibitors |
EP3099300B1 (en) * | 2014-01-29 | 2018-09-05 | Bristol-Myers Squibb Company | Aryl lactam kinase inhibitors |
WO2018022851A1 (en) | 2016-07-28 | 2018-02-01 | Mitobridge, Inc. | Methods of treating acute kidney injury |
EP3534957A1 (en) | 2016-11-02 | 2019-09-11 | Immunogen, Inc. | Combination treatment with antibody-drug conjugates and parp inhibitors |
MX2022000711A (en) * | 2019-07-19 | 2022-02-23 | Astrazeneca Ab | Parp1 inhibitors. |
TW202304911A (en) * | 2021-04-23 | 2023-02-01 | 大陸商南京明德新藥研發有限公司 | Pyridinamide compound |
WO2022223022A1 (en) * | 2021-04-23 | 2022-10-27 | 四川海思科制药有限公司 | Fused-ring heterocycle derivative and medical application thereof |
TWI820847B (en) * | 2021-08-05 | 2023-11-01 | 大陸商上海樞境生物科技有限公司 | Regulators containing tricyclic derivatives, preparation methods and applications thereof |
WO2023025307A1 (en) * | 2021-08-27 | 2023-03-02 | Impact Therapeutics (Shanghai) , Inc | Substituted tricyclic compounds as parp inhibitors and use thereof |
WO2023061406A1 (en) * | 2021-10-12 | 2023-04-20 | 微境生物医药科技(上海)有限公司 | Parp inhibitor containing fused tri-cyclic structure, and preparation method therefor and medical use thereof |
WO2023169226A1 (en) * | 2022-03-11 | 2023-09-14 | Impact Therapeutics (Shanghai), Inc | Substituted tricyclic compounds as parp inhibitors and the use thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999011624A1 (en) * | 1997-09-03 | 1999-03-11 | Guilford Pharmaceuticals Inc. | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
WO2001042219A2 (en) * | 1999-12-07 | 2001-06-14 | Inotek Corporation | Novel substituted phenanthridinones and methods of use thereof |
WO2001090077A1 (en) * | 2000-05-19 | 2001-11-29 | Guilford Pharmaceuticals, Inc. | Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2777189B1 (en) * | 1998-04-09 | 2001-04-06 | Chauvin Lab Sa | OPHTHALMIC COMPOSITION COMPRISING A BETA-BLOCKER |
-
2002
- 2002-03-26 AU AUPS1374A patent/AUPS137402A0/en not_active Abandoned
-
2003
- 2003-03-25 CA CA002480384A patent/CA2480384A1/en not_active Abandoned
- 2003-03-25 JP JP2003578336A patent/JP2005521698A/en active Pending
- 2003-03-25 EP EP03712891A patent/EP1487800A1/en not_active Withdrawn
- 2003-03-25 WO PCT/JP2003/003579 patent/WO2003080581A1/en not_active Application Discontinuation
- 2003-03-25 US US10/508,004 patent/US20050171101A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999011624A1 (en) * | 1997-09-03 | 1999-03-11 | Guilford Pharmaceuticals Inc. | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
WO2001042219A2 (en) * | 1999-12-07 | 2001-06-14 | Inotek Corporation | Novel substituted phenanthridinones and methods of use thereof |
WO2001090077A1 (en) * | 2000-05-19 | 2001-11-29 | Guilford Pharmaceuticals, Inc. | Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses |
Cited By (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US7196085B2 (en) | 2002-04-30 | 2007-03-27 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US7662818B2 (en) | 2003-03-12 | 2010-02-16 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US9169235B2 (en) | 2003-03-12 | 2015-10-27 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US8912187B2 (en) | 2003-03-12 | 2014-12-16 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US10449192B2 (en) | 2003-03-12 | 2019-10-22 | Kudo Pharmaceuticals Limited | Phthalazinone derivatives |
US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US11160803B2 (en) | 2003-03-12 | 2021-11-02 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US9566276B2 (en) | 2003-03-12 | 2017-02-14 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US8524714B2 (en) | 2003-11-20 | 2013-09-03 | Janssen Pharmaceutica, Nv | 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors |
EP2305221A1 (en) | 2003-12-01 | 2011-04-06 | Kudos Pharmaceuticals Limited | Dna damage repair inhibitors for treatment of cancer |
US20110230491A1 (en) * | 2003-12-05 | 2011-09-22 | Dominique Jean-Pierre Mabire | 6-substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors |
US9522905B2 (en) | 2004-06-30 | 2016-12-20 | Janssen Pharmaceutica Nv | Quinazolinone derivatives as PARP inhibitors |
US8623872B2 (en) | 2004-06-30 | 2014-01-07 | Janssen Pharmaceutica, Nv | Quinazolinone derivatives as PARP inhibitors |
US10150757B2 (en) | 2004-06-30 | 2018-12-11 | Janssen Pharmaceutica Nv | Quinazolinone derivatives as PARP inhibitors |
US8946221B2 (en) | 2004-06-30 | 2015-02-03 | Janssen Pharmaceutica, Nv | Phthalazine derivatives as PARP inhibitors |
US7902193B2 (en) | 2005-10-19 | 2011-03-08 | Maybridge Limited | Phthalazinone derivatives |
US7470688B2 (en) | 2005-10-19 | 2008-12-30 | Maybridge Limited | Phthalazinone derivatives |
WO2008090379A1 (en) * | 2007-01-24 | 2008-07-31 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Pyrazoloquinazolinones as inhibitors of poly(adp-ribose)polymerase (parp) |
US8778966B2 (en) | 2007-03-08 | 2014-07-15 | Janssen Pharmaceutica, Nv | Quinolinone derivatives as PARP and tank inhibitors |
US8299256B2 (en) | 2007-03-08 | 2012-10-30 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP and TANK inhibitors |
WO2009041565A1 (en) * | 2007-09-26 | 2009-04-02 | Santen Pharmaceutical Co., Ltd. | Quinazolinone derivative, and prophylactic or therapeutic agent for corneal/conjunctival disorder comprising quinazolinone derivative as active ingredient |
WO2009041566A1 (en) * | 2007-09-26 | 2009-04-02 | Santen Pharmaceutical Co., Ltd. | Preventive or remedy for posterior eye diseases containing quinazolinone derivative or quinoxaline derivative as the active ingredient |
US8404713B2 (en) | 2007-10-26 | 2013-03-26 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP inhibitors |
WO2009061131A3 (en) * | 2007-11-06 | 2009-06-25 | Je Il Pharmaceutical Co Ltd | Novel tricyclic derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same |
WO2009061131A2 (en) * | 2007-11-06 | 2009-05-14 | Je Il Pharmaceutical Co., Ltd. | Novel tricyclic derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same |
US8889866B2 (en) | 2008-03-27 | 2014-11-18 | Janssen Pharmaceutica, Nv | Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors |
US20150038521A1 (en) * | 2008-03-27 | 2015-02-05 | Janssen Pharmaceutica, Nv | Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors |
US9150540B2 (en) | 2008-03-27 | 2015-10-06 | Janssen Pharmaceutica Nv | Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors |
US9598396B2 (en) | 2008-03-27 | 2017-03-21 | Janssen Pharmaceutica Nv | Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors |
US8168644B2 (en) | 2008-03-27 | 2012-05-01 | Janssen Pharmaceutica Nv | Quinazolinone derivatives as tubulin polymerization inhibitors |
US12048695B2 (en) | 2008-10-07 | 2024-07-30 | Kudos Pharmaceuticals Limited | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
US11975001B2 (en) | 2008-10-07 | 2024-05-07 | Kudos Pharmaceuticals Limited | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
US11633396B2 (en) | 2008-10-07 | 2023-04-25 | Kudos Pharmaceuticals Limited | Immediate release pharmaceutical formulation of 4-[3-(4- cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H- phthalazin-1-one |
US8475842B2 (en) | 2008-10-07 | 2013-07-02 | Astrazeneca Ab | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
US9163003B2 (en) | 2011-07-13 | 2015-10-20 | Novartis Ag | 4-piperidinyl compounds for use as tankyrase inhibitors |
US9181266B2 (en) | 2011-07-13 | 2015-11-10 | Novartis Ag | 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors |
USRE46942E1 (en) | 2011-07-13 | 2018-07-10 | Novartis Ag | 4-piperidinyl compounds for use as tankyrase inhibitors |
US9227982B2 (en) | 2011-07-13 | 2016-01-05 | Novartis Ag | 4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrminidinyl compounds for use as tankyrase inhibitors |
CN104507941A (en) * | 2012-07-31 | 2015-04-08 | 百时美施贵宝公司 | Aryl lactam kinase inhibitors |
US10464919B2 (en) | 2015-06-09 | 2019-11-05 | Je Il Pharmaceutical Co., Ltd. | Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same |
EP3312177A4 (en) * | 2015-06-09 | 2018-12-05 | Jeil Pharmaceutical Co., Ltd. | Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same |
WO2018197461A1 (en) | 2017-04-28 | 2018-11-01 | Akribes Biomedical Gmbh | A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing |
WO2019175132A1 (en) | 2018-03-13 | 2019-09-19 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
WO2021048235A1 (en) | 2019-09-10 | 2021-03-18 | The Francis Crick Institute Limited | Treatment of hr deficient cancer |
US11591331B2 (en) | 2021-04-19 | 2023-02-28 | Xinthera, Inc. | PARP1 inhibitors and uses thereof |
WO2022228387A1 (en) * | 2021-04-26 | 2022-11-03 | Fochon Biosciences, Ltd. | Compounds as parp inhibitors |
US11802128B2 (en) | 2021-10-01 | 2023-10-31 | Xinthera, Inc. | Azetidine and pyrrolidine PARP1 inhibitors and uses thereof |
US11939329B2 (en) | 2022-01-21 | 2024-03-26 | Xinthera, Inc. | PARP1 inhibitors and uses thereof |
US12006322B2 (en) | 2022-04-28 | 2024-06-11 | Xin Thera, Inc. | Substituted pyridines as PARP1 inhibitors |
US11795173B1 (en) | 2022-04-28 | 2023-10-24 | Xinthera, Inc. | Substituted pyridines as PARP1 inhibitors |
Also Published As
Publication number | Publication date |
---|---|
JP2005521698A (en) | 2005-07-21 |
US20050171101A1 (en) | 2005-08-04 |
CA2480384A1 (en) | 2003-10-02 |
EP1487800A1 (en) | 2004-12-22 |
AUPS137402A0 (en) | 2002-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003080581A1 (en) | Phenanthridinones as parp inhibitors | |
JP7311228B2 (en) | RHO-related protein kinase inhibitors, pharmaceutical compositions containing same and methods for preparation and use thereof | |
CN108602776B (en) | Heteroaryl compounds as IRAK inhibitors and uses thereof | |
KR101712441B1 (en) | Aryl and heteroaryl fused lactams | |
CN109790169A (en) | With the Cyanopyrolidine derivatives as USP30 inhibitor activity | |
CN108290879B (en) | Heteroaryl compounds as IRAK inhibitors and uses thereof | |
JP5649445B2 (en) | Compounds useful as RAF kinase inhibitors | |
JP2019508467A (en) | 2-Cyanoisoindoline derivatives for cancer treatment | |
KR102530580B1 (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
EP3283472A1 (en) | Hepatitis b viral assembly effectors | |
CA2982588A1 (en) | Bromodomain inhibitors | |
AU2014249003A1 (en) | Novel compounds and compositions for inhibition of FASN | |
WO2012008563A1 (en) | Nitrogenated aromatic heterocyclic ring derivative | |
WO2003063874A1 (en) | Condensed heterocyclic compounds | |
WO1993004047A1 (en) | Quinazoline derivatives as inhibitors of hiv reverse transcriptase | |
EP2462123A1 (en) | 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors | |
EP2809652B1 (en) | Isoquinoline and naphthyridine derivatives | |
EP3057957B1 (en) | Cyclopentylbenzamide derivatives and their use for the treatment of psychotic and cognitive disorders | |
CN109988093B (en) | Amine compound for inhibiting SSAO/VAP-1 and application thereof in medicine | |
WO2005019188A1 (en) | Fused pyrimidine derivative and use thereof | |
CA2731873A1 (en) | 1,2,4-oxadiazole substituted piperidine and piperazine derivatives as smo antagonists | |
AU2010285621A1 (en) | Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation | |
CA3073794A1 (en) | Fused [1,2,4]thiadiazine derivatives which act as kat inhibitors of the myst family | |
JP2009504753A (en) | A novel high affinity quinoline-based kinase ligand | |
KR20210113287A (en) | Halo-allylamine compounds and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003712891 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003578336 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10508004 Country of ref document: US Ref document number: 2480384 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 2003712891 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003712891 Country of ref document: EP |